Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OGT | O15294 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337871 | 0.84 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2337859 | 0.84 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6136114 | 0.82 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL28148332 | 0.82 | TK1 (0.37) | ALDH1A1LMNA | |
| SCHEMBL29134987 | 0.81 | TK2 (0.35) | — | |
| SCHEMBL9237885 | 0.80 | LMNA (0.37) | LMNA | |
| SCHEMBL381848 | 0.79 | PDE3A (0.41) | SLC29A1ALDH1A1LMNA | |
| SCHEMBL28289547 | 0.77 | TK2 (0.46) | — | |
| SCHEMBL12813023 | 0.75 | DNMT1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL1285619 | 0.75 | POLB (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9418 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| WO-2024162590-A1 | COMPOSITION FOR PREVENTING OR TREATING PROSTATIC HYPERTROPHY, CONTAINING, AS ACTIVE INGREDIENTS, SALVIA MILTIORRHIZA BUNGE EXTRACT, METAL MINERAL DIAMINATE AND URIDINE | 주식회사 건강중심주의 | 2024-08-08 | — | — | WO | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| CN-112301118-B | Method and kit for simultaneously obtaining RNA abundance and active RNA polymerase sites in full transcriptome range | 浙江大学 | 2022-05-13 | — | — | CN | claimed |
| WO-2021261855-A1 | ZINC TRANSPORTER ACTIVATOR COMPOSITION | 주식회사 메타센테라퓨틱스 | 2021-12-30 | — | — | WO | claimed |
| US-11207289-B2 | Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis | ACADEMIA SINICA (TW) | 2021-12-28 | — | — | US | claimed |
| US-20210154200-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | ONCOCEUTICS, INC. (US) | 2021-05-27 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996001115-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1996-01-18 | — | — | WO | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0679160-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1995-11-02 | — | — | EP | claimed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| CN-1095268-A | Pyrimidine nucleotide precursors for the treatment of systemic inflammation and inflammatory hepatitis | PRO NEURON INC (US) | 1994-11-23 | — | — | CN | claimed |
| WO-1994013687-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1994-06-23 | — | — | WO | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| CN-1071577-A | Handle the toxicity of chemotherapy reagent and Anti-virus agent with acylated pyrimidine nucleosides | PRO NEURON INC (US) | 1993-05-05 | — | — | CN | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |